Search Results - "Shore N"

Minicomputer online control of D. C. link converters.

Authors: Shore, N. L. Freis, L. L.

Source: Proceedings of the Institution of Electrical Engineers; March 1978, Vol. 125, p215-220, 6p

DC side filters for multiterminal HVDC systems.

Authors: Shore, N. L. Adamson, K. Bard, P.

Source: IEEE Transactions on Power Delivery; October 1996, Vol. 11, p1970-1984, 15p

A three-pulse model of D.C. side harmonic flow in HVDC systems.

Authors: Shore, N. L. Andersson, G. Canelhas, A. P.

Source: IEEE Transactions on Power Delivery; July 1989, Vol. 4, p1945-1952, 8p

Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?

Authors: Shore, N D¹

Source: Prostate Cancer & Prostatic Diseases. Mar2013, Vol. 16 Issue 1, p1-6. 6p.

New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.

Authors: Shore, N D Abrahamsson, P-A Anderson, J et al.

Source: Prostate Cancer & Prostatic Diseases. Mar2013, Vol. 16 Issue 1, p7-15. 9p.

New developments in castrate-resistant prostate cancer.

Authors: Shore, N. Masont, M. de Reijke, Th. M.

Source: BJU International. Jun2012 Supplement, Vol. 109, p22-32. 11p.

Re-conceptualizing the Belmont Report: a community-based participatory research perspective.

Authors: Shore N (AUTHOR)

Source: Journal of Community Practice. 2006, Vol. 14 Issue 4, p5-26. 22p.

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.

Authors: Fizazi, K. Shore, N. Tammela, T. L. et al.

Source: New England Journal of Medicine. 9/10/2020, Vol. 383 Issue 11, p1040-1049. 10p.

Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in Men with High-Risk Biochemically Recurrent Prostate Cancer and Prior Radiotherapy: EMBARK Subgroup Analysis.

Authors: Sridharan, S. Shore, N. Venugopal, B. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. Nov2023, Vol. 117 Issue 4, pe4-e5. 2p.

Subjects: Cancer radiotherapy, Leuprolide, Radiotherapy, Prostate cancer, Subgroup analysis (Experimental design), Placebos

Challenges and Solutions during the COVID Pandemic for Patient Retention and Physician Engagement in the Phase 3 ATLAS Study of Apalutamide Added to Androgen Deprivation Therapy (ADT) in High-Risk Localized or Locally Advanced Prostate Cancer (HRLPC).

Authors: Sandler, H.M. Shore, N. Dearnaley, D. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2022 Supplement, Vol. 114 Issue 3, pe244-e245. 2p.

Subjects: Androgen deprivation therapy, COVID-19 pandemic, Watchful waiting, External beam radiotherapy, Prostate cancer, Physician engagement

Relugolix, A Novel Oral GnRH Receptor Antagonist, versus Leuprolide Depot for Prostate Cancer: The HERO Phase 3 Trial.

Authors: Spratt, D.E. Shore, N. Bossi, A. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2020 Supplement, Vol. 108 Issue 3, pS18-S19. 2p.

Subjects: Leuprolide, Luteinizing hormone releasing hormone receptors, Prostate cancer, Castration-resistant prostate cancer

661P Real-world treatment (Tx) patterns of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the US.

Authors: Shore, N. Laliberté, F. Ionescu-Ittu, R. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS534-S535. 2p.

654P Real-world treatment (Tx) patterns in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm+).

Authors: Shore, N. Ionescu-Ittu, R. Laliberté, F. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS531-S532. 2p.

641P Real-world patterns of genomic testing in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).

Authors: Shore, N. Ionescu-Ittu, R. Yang, L. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS526-S527. 2p.

A0332 - A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with Bacillus Calmette-Guérin unresponsive high-risk non-muscle invasive bladder cancer: CREST study cohort B.

Authors: Shore, N. Powles, T.B. Bedke, J. et al.

Source: European Urology. 2022 Supplement 1, Vol. 81, pS512-S512. 1p.

691TiP A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status

Authors: De Giorgi, U. Shore, N. Sridharan, S. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS547-S547. 1p.

633P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial.

Authors: Fizazi, K. Shore, N. Smith, M.R. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS522-S522. 1p.

Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.

Authors: Freedland, S. J. Eastham, J. Shore, N.

Source: Prostate Cancer & Prostatic Diseases. 2009, Vol. 12 Issue 4, p333-338. 6p. 1 Diagram, 1 Chart.

CCP Score Stratifies Risk for Prostate Cancer Patients at Biopsy: Initial Commercial Results.

Authors: Crawford, E. Shore, N. Scardino, P. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. Sep2014 Supplement, Vol. 90 Issue 1, pS433-S433. 1p.

Subjects: Prostate cancer patients, Prostate cancer treatment, Biopsy, Cell cycle, Biomarkers

UP-02.068 Central Venous Catheter Utilization During the IMPACT (D9902B) Trial: a Review of Central Venous Catheter Incidence and Associated Adverse Events

Authors: Shore, N. Corman, J. Whitmore, J. et al.

Source: Urology. Sep2011 Supplement, Vol. 78, pS283-S283. 1p.